A detailed history of Camber Capital Management LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Camber Capital Management LP holds 850,000 shares of APLS stock, worth $17.3 Million. This represents 1.45% of its overall portfolio holdings.

Number of Shares
850,000
Holding current value
$17.3 Million
% of portfolio
1.45%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$16.36 - $23.0 $13.9 Million - $19.6 Million
850,000 New
850,000 $14.7 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.23B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Camber Capital Management LP Portfolio

Follow Camber Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Camber Capital Management LP with notifications on news.